top of page
< Back

Zepbound

MED-000004

Tirzepatide for chronic weight management.

Medication Overview

Generic Name: 

Medication Class: 

Manufacturer:

Route:

Dosing Frequency:

Tirzepatide

GLP-1/GIP

Eli Lilly

Injection

Weekly

Status:

Draft

Medication Summary

Tirzepatide for chronic weight management.

Aliases

Zepbound

Search Keywords

zepbound, tirzepatide

Medication Uses

Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.

Zepbound® (tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management, used together with a reduced-calorie diet and increased physical activity.  Approved uses include: - Adults with obesity (BMI ≥30 kg/m²) - Adults who are overweight (BMI ≥27 kg/m²) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia - Moderate-to-severe obstructive sleep apnea in adults with obesity — a distinct FDA approval separate from the weight-management indication  Zepbound is not approved for type 1 diabetes. Zepbound and Mounjaro should never be used together, since they contain the same active ingredient.

Dosage

Zepbound is injected once weekly, subcutaneously, using the same titration schedule as Mounjaro:  - Weeks 1–4: 2.5 mg - Weeks 5–8: 5 mg - Weeks 9–12: 7.5 mg - Weeks 13–16: 10 mg - Weeks 17–20: 12.5 mg - Week 21 onward: 15 mg (maximum dose)  Approved maintenance doses are 5 mg, 10 mg, or 15 mg — reaching the maximum dose isn't required for meaningful results; the 5 mg maintenance dose alone produced approximately 15% average weight loss at 72 weeks in clinical trials. Missed doses can be taken within 4 days; otherwise, skip and resume your regular schedule.

Administration

Subcutaneous injection, once weekly, any time of day, with or without food. Inject into the abdomen, thigh, or upper arm, rotating sites regularly to reduce irritation.

Benefits

When prescribed appropriately and combined with lifestyle changes, Zepbound may help: - Support substantial, sustained weight loss — up to approximately 22.5% of body weight at 72 weeks at the maximum dose in clinical trials - Reduce appetite and increase feelings of fullness - Improve obstructive sleep apnea severity in adults with obesity - Improve weight-related health markers in eligible patients  Results vary between individuals and depend on consistent use alongside nutrition and activity changes.

Side Effects

The most frequently reported side effects include: - Nausea - Diarrhea - Vomiting - Constipation - Abdominal pain - Injection-site reactions - Decreased appetite  Most noticeable during dose escalation, often improving with continued use.

Warnings

Zepbound carries an FDA boxed warning regarding thyroid C-cell tumor risk observed in rodent studies. Contraindicated in patients with: - A personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)  Other important warnings include: - Pancreatitis - Acute kidney injury, typically linked to dehydration from GI side effects - Gallbladder disease - Severe gastrointestinal disease — Zepbound may worsen existing severe GI conditions - Serious hypersensitivity reactions  Seek immediate medical attention for severe abdominal pain, difficulty breathing, or facial/throat swelling.

Drug Interactions

Particular caution is needed with: - Insulin and sulfonylureas — increased hypoglycemia risk - Oral hormonal contraceptives — Zepbound has been shown to meaningfully reduce peak drug concentrations; discuss alternative contraception with your provider - Oral medications generally — delayed gastric emptying can affect absorption

Storage

Before first use: refrigerate at 36°F–46°F (2°C–8°C). Do not freeze. After first use: refrigerate, or store at room temperature (up to 86°F/30°C) for up to 21 days. Protect from light and heat. Keep out of reach of children.

References

- U.S. FDA prescribing information for Zepbound® - DailyMed prescribing information - Obesity Medicine Association clinical resources - Eli Lilly Healthcare Professional prescribing information

Last medically reviewed and updated: July 11, 2026.

Track Your Progress

Weight management with Zepbound is a long-term journey. With DietApp.com, you can: - Record weekly injections and titration progress - Track body weight and BMI over time - Monitor waist measurements and body composition - Log meals, physical activity, and hydration - Record side effects and symptoms - Prepare an organized treatment history for healthcare appointments

Download DietApp.com

Related Resources

- Tirzepatide Medication Guide - Mounjaro Medication Guide - GLP-1 Medication Library - Weight Management Resources - GLP-1 Injection Guide - Medication Safety Information

Related Articles

- What Is Tirzepatide? - Mounjaro vs. Zepbound: What's the Difference? - Tirzepatide Side Effects: What Patients Need to Know - How GLP-1 Medications Support Weight Management - Frequently Asked Questions About GLP-1 Therapy

More From DietApp.com

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Explore DietApp.com Tools

- BMI Calculator — Get an instant estimate and see what it does (and doesn't) tell you about your health - GLP-1 Dose & Injection Tracker — Log your weekly dose and rotate injection sites automatically - AI Food Recognition — Snap a photo of your meal for instant protein, fiber, and calorie tracking - Protein & Hydration Dashboard — See your daily totals at a glance - Symptom & Side Effect Log — Track patterns over time to bring to your next appointment - Download DietApp — Start tracking your GLP-1 journey today

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

bottom of page